Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

Incyte (INCY) announced that the late-stage inMIND study on tafasitamab met its primary and secondary endpoints. This phase III study is evaluating the efficacy and safety of tafasitamab, a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, or placebo in combination with Revlimid and Rituxan compared to Revlimid and Rituxan alone in patients with relapsed or refractory follicular lymphoma (FL). The trial met its primary endpoint of progression free survival (PFS) by investigator assessment ...